semaglutide and eye disease linked to risk of rare condition GLP-1 Drugs and Diabetic Eye

I think that both the experimental model proposed by the authors and the measures that they have carried out are accurate

Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date

This treatment was subsequently widely used in other parts of the world (168, 169)

The effects of GLP-1s increase postprandial insulin secretion from pancreatic -cells, suppress glucagon secretion from -cells, slow gastric emptying, and reduce appetite (Gross)